ATE210826T1 - Verfahren zur bestimmung von cyclooxygenase-1- aktivität - Google Patents
Verfahren zur bestimmung von cyclooxygenase-1- aktivitätInfo
- Publication number
- ATE210826T1 ATE210826T1 AT96201845T AT96201845T ATE210826T1 AT E210826 T1 ATE210826 T1 AT E210826T1 AT 96201845 T AT96201845 T AT 96201845T AT 96201845 T AT96201845 T AT 96201845T AT E210826 T1 ATE210826 T1 AT E210826T1
- Authority
- AT
- Austria
- Prior art keywords
- activity
- determining
- cyclooxygenase
- sample
- determining cyclooxygenase
- Prior art date
Links
- 102000010906 Cyclooxygenase 1 Human genes 0.000 title 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 1
- 229940114079 arachidonic acid Drugs 0.000 abstract 1
- 235000021342 arachidonic acid Nutrition 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/61—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving triglycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/99—Miscellaneous (1.14.99)
- C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99476092A | 1992-12-22 | 1992-12-22 | |
| US08/064,271 US5543297A (en) | 1992-12-22 | 1993-05-06 | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE210826T1 true ATE210826T1 (de) | 2001-12-15 |
Family
ID=26744337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94902571T ATE155811T1 (de) | 1992-12-22 | 1993-12-17 | Menschliche cyclooxygenase-2cdna und bestimmung von menschliche cyclooxygenase-2-inhibierung |
| AT96201845T ATE210826T1 (de) | 1992-12-22 | 1993-12-17 | Verfahren zur bestimmung von cyclooxygenase-1- aktivität |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94902571T ATE155811T1 (de) | 1992-12-22 | 1993-12-17 | Menschliche cyclooxygenase-2cdna und bestimmung von menschliche cyclooxygenase-2-inhibierung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5543297A (de) |
| EP (3) | EP0675964B1 (de) |
| JP (2) | JP3608622B2 (de) |
| AT (2) | ATE155811T1 (de) |
| AU (1) | AU5690694A (de) |
| CA (1) | CA2151231C (de) |
| DE (2) | DE69312513T2 (de) |
| DK (1) | DK0675964T3 (de) |
| ES (2) | ES2168436T3 (de) |
| GR (1) | GR3025111T3 (de) |
| WO (1) | WO1994014977A1 (de) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837479A (en) * | 1992-09-22 | 1998-11-17 | Young; Donald A. | Screening assays for inhibitors of mammalian prostaglandin H synthase-2 |
| CA2172611A1 (en) * | 1993-09-27 | 1995-04-06 | Gary P. O'neill | High level expression of human cyclooxygenase-2 |
| WO1995016466A1 (en) * | 1993-12-17 | 1995-06-22 | The Ohio State University | Antisense oligonucleotides to suppress eicosanoid formation |
| US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| AT401061B (de) * | 1995-01-26 | 1996-06-25 | Hafslund Nycomed Pharma | Benutzung einer menschlichen monozytenartigen zellinie zur identifikation und bestimmung von substanzen zur hemmung des menschlichen enzyms cyclooxygenase-2 |
| WO1996040720A1 (en) * | 1995-06-07 | 1996-12-19 | University Of Rochester | Mammalian prostaglandin h synthase-2 |
| JPH0977664A (ja) * | 1995-09-13 | 1997-03-25 | Yakult Honsha Co Ltd | シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤 |
| WO1997031631A1 (en) * | 1996-02-27 | 1997-09-04 | Rpms Technology Limited | Cox-2 selective inhibitors for managing labour and uterine contractions |
| AT402936B (de) * | 1996-05-29 | 1997-09-25 | Nycomed Austria Gmbh | Benutzung einer menschlichen zellinie zur identifikation und bestimmung von substanzen zur hemmung der induktion der expression des cyclooxygenase-2-genes |
| GB2319032A (en) * | 1996-10-04 | 1998-05-13 | Merck & Co Inc | Crystals of human cyclooxygenase-2 (hCOX-2) |
| US5985930A (en) * | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
| EP1138324A1 (de) * | 1996-11-21 | 2001-10-04 | The Mount Sinai School of Medicine of New York University | Behandlung von Neurodegenerativen zuständen Mittels Nimesulide |
| WO1998037235A1 (en) * | 1997-02-24 | 1998-08-27 | Cornell Research Foundation, Inc. | Method of screening agents as candidates for drugs or sources of drugs |
| JP2001514663A (ja) * | 1997-03-12 | 2001-09-11 | エスモンド，ロバート ダブリュー． | アルツハイマー病を処置または予防するための方法 |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
| ES2267263T3 (es) * | 1998-04-15 | 2007-03-01 | Emd Lexigen Research Center Corp. | Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo. |
| WO1999067283A2 (en) | 1998-06-24 | 1999-12-29 | University Of Dundee | Two-kinase domain mitogen- and stress-activated protein kinases and uses thereof |
| CA2347365A1 (en) * | 1998-10-23 | 2000-05-04 | Merck Frosst Canada & Co. | Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| GB9827430D0 (en) * | 1998-12-11 | 1999-02-03 | Ludwig Inst Cancer Res | Differential expression in primary breast cancer |
| US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
| WO2000077245A1 (en) * | 1999-06-16 | 2000-12-21 | Temple University - Of The Commonwealth System Of Higher Education | Cell-based assay for screening cox-2 inhibitors |
| US6933128B1 (en) | 1999-06-16 | 2005-08-23 | Temple University-Of The Commonwealth System Of Higher Education | Cell-based assay for screening cox-2 inhibitors |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| AR025049A1 (es) * | 1999-08-06 | 2002-11-06 | Searle & Co | Ciclooxigenasa-1 (cox-1) y ciclooxigenasa-2 (cox-2) caninas. |
| US6617135B1 (en) * | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| CO5261556A1 (es) * | 1999-12-08 | 2003-03-31 | Pharmacia Corp | Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico |
| CA2398995C (en) * | 2000-02-04 | 2014-09-23 | Children's Hospital Research Foundation | Lipid hydrolysis therapy for atherosclerosis and related diseases |
| DK1252192T3 (da) * | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
| RU2272644C2 (ru) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| CA2414674A1 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| WO2002007721A2 (en) * | 2000-07-20 | 2002-01-31 | Lauras As | Use of cox-2 inhibitors for preventing immunodeficiency |
| CA2422803A1 (en) * | 2000-08-07 | 2002-02-14 | Vanderbilt University | Detection of cox-2 activity and anandamide metabolites |
| WO2002050310A2 (en) * | 2000-12-20 | 2002-06-27 | The Regents Of The University Of California | Rolling circle amplification detection of rna and dna |
| WO2002057792A2 (en) * | 2000-12-29 | 2002-07-25 | Neogenesis Pharmaceuticals, Inc. | Affinity selection-based screening of hydrophobic proteins |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| KR100900176B1 (ko) * | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
| US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| MY137736A (en) | 2001-04-03 | 2009-03-31 | Pharmacia Corp | Reconstitutable parenteral composition |
| CA2446087C (en) * | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
| UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
| DE60238872D1 (de) * | 2001-09-28 | 2011-02-17 | Univ Brigham Young | Neue cyclooxygenase-varianten und verwendungsverfahren |
| BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US7670769B2 (en) | 2002-05-09 | 2010-03-02 | The Brigham And Women's Hospital, Inc. | IL1RL-1 as a cardiovascular disease marker and therapeutic target |
| US7314709B2 (en) * | 2002-08-06 | 2008-01-01 | Vanderbilt University | Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism |
| JP4494977B2 (ja) * | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 |
| US7491743B2 (en) | 2003-08-29 | 2009-02-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| EP1809759B1 (de) | 2004-10-06 | 2013-09-11 | The Brigham And Women's Hospital, Inc. | Relevanz erzielter niveaus von markern für systemische entzündung nach behandlung |
| WO2006083779A2 (en) * | 2005-01-31 | 2006-08-10 | Mylan Laboratories, Inc. | Pharmaceutical composition comprising hydroxylated nebivolol |
| WO2006116702A2 (en) * | 2005-04-28 | 2006-11-02 | The Johns Hopkins University | Inducible nitric oxide synthase binds, s-nitrosylates, and activates cyclooxygenase-2 |
| NZ563759A (en) | 2005-05-31 | 2010-06-25 | Mylan Lab Inc | Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate |
| US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| PL2001496T3 (pl) | 2006-03-15 | 2017-10-31 | Brigham & Womens Hospital Inc | Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych |
| WO2007127965A1 (en) | 2006-04-28 | 2007-11-08 | Mayo Foundation For Medical Education And Research | Treating glaucoma, cardiovascular diseases, and renal diseases |
| WO2007146229A2 (en) * | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| BRPI0810409A2 (pt) | 2007-04-18 | 2015-02-18 | Thethys Bioscience Inc | Biomarcadores relacionados ao diabetes e métodos de uso destes |
| CA2788571A1 (en) | 2010-02-01 | 2011-08-04 | Andrew Redington | Remote ischemic conditioning for treatment and prevention of restenosis |
| EP2552331B1 (de) | 2010-03-31 | 2020-01-08 | The Hospital For Sick Children | Verwendung ischämischer remote-konditionierungen zur verbesserung der ergebnisse nach myokardinfarkten |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| RU2706366C2 (ru) * | 2017-11-01 | 2019-11-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ПГФА Минздрава России) | Способ отбора противовоспалительных средств с использованием рассчитанных энергий взаимодействия с ферментами циклооксигеназ 1 и 2 |
| EP4509118A3 (de) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | Hochreine peg-lipide und verwendungen davon |
| WO2020061284A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562155A (en) * | 1983-05-19 | 1985-12-31 | The Wistar Institute Of Anatomy And Biology | Hybrid viral plasmid and microorganisms containing same |
| JPS63157980A (ja) | 1986-12-22 | 1988-06-30 | Chisso Corp | プロスタグランジン合成酵素の安定化方法 |
| JPH01228479A (ja) * | 1988-03-10 | 1989-09-12 | Meiji Milk Prod Co Ltd | プロスタグランジンエンドペルオキシドシンテターゼをコードするｄｎａ |
| US6048850A (en) | 1992-09-22 | 2000-04-11 | Young; Donald A. | Method of inhibiting prostaglandin synthesis in a human host |
| US5837479A (en) | 1992-09-22 | 1998-11-17 | Young; Donald A. | Screening assays for inhibitors of mammalian prostaglandin H synthase-2 |
| ATE179756T1 (de) * | 1992-09-22 | 1999-05-15 | Univ Rochester | Stabil transformierte säugertierzellen, die eine geregelte, entzündliche cyclooxygenase exprimieren |
| JPH06315798A (ja) * | 1993-05-07 | 1994-11-15 | Kobe Steel Ltd | 高エネルギービーム溶接用裏当材 |
-
1993
- 1993-05-06 US US08/064,271 patent/US5543297A/en not_active Expired - Lifetime
- 1993-12-17 ES ES96201845T patent/ES2168436T3/es not_active Expired - Lifetime
- 1993-12-17 DE DE69312513T patent/DE69312513T2/de not_active Expired - Fee Related
- 1993-12-17 ES ES94902571T patent/ES2105611T3/es not_active Expired - Lifetime
- 1993-12-17 JP JP51463294A patent/JP3608622B2/ja not_active Expired - Fee Related
- 1993-12-17 EP EP94902571A patent/EP0675964B1/de not_active Expired - Lifetime
- 1993-12-17 EP EP01201784A patent/EP1130110A3/de not_active Withdrawn
- 1993-12-17 WO PCT/CA1993/000547 patent/WO1994014977A1/en not_active Ceased
- 1993-12-17 DE DE69331340T patent/DE69331340T2/de not_active Expired - Fee Related
- 1993-12-17 AT AT94902571T patent/ATE155811T1/de not_active IP Right Cessation
- 1993-12-17 DK DK94902571.2T patent/DK0675964T3/da active
- 1993-12-17 AT AT96201845T patent/ATE210826T1/de not_active IP Right Cessation
- 1993-12-17 AU AU56906/94A patent/AU5690694A/en not_active Abandoned
- 1993-12-17 EP EP96201845A patent/EP0736769B1/de not_active Expired - Lifetime
- 1993-12-17 CA CA002151231A patent/CA2151231C/en not_active Expired - Fee Related
-
1997
- 1997-10-21 GR GR970402753T patent/GR3025111T3/el unknown
-
2000
- 2000-11-20 US US09/731,632 patent/USRE39696E1/en not_active Expired - Fee Related
-
2003
- 2003-06-27 JP JP2003184084A patent/JP3573743B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GR3025111T3 (en) | 1998-01-30 |
| DE69331340T2 (de) | 2002-08-22 |
| HK1027471A1 (en) | 2001-01-12 |
| JPH08504584A (ja) | 1996-05-21 |
| ATE155811T1 (de) | 1997-08-15 |
| EP1130110A3 (de) | 2005-02-23 |
| AU5690694A (en) | 1994-07-19 |
| USRE39696E1 (en) | 2007-06-19 |
| JP3608622B2 (ja) | 2005-01-12 |
| ES2105611T3 (es) | 1997-10-16 |
| DK0675964T3 (da) | 1997-09-15 |
| EP0736769A1 (de) | 1996-10-09 |
| EP0675964B1 (de) | 1997-07-23 |
| US5543297A (en) | 1996-08-06 |
| EP0675964A1 (de) | 1995-10-11 |
| EP1130110A2 (de) | 2001-09-05 |
| DE69312513T2 (de) | 1998-01-15 |
| ES2168436T3 (es) | 2002-06-16 |
| CA2151231A1 (en) | 1994-07-07 |
| DE69331340D1 (de) | 2002-01-24 |
| WO1994014977A1 (en) | 1994-07-07 |
| JP2004081211A (ja) | 2004-03-18 |
| CA2151231C (en) | 2004-11-09 |
| EP0736769B1 (de) | 2001-12-12 |
| JP3573743B2 (ja) | 2004-10-06 |
| DE69312513D1 (de) | 1997-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69331340D1 (de) | Verfahren zur Bestimmung von Cyclooxygenase-1-Aktivität | |
| DE3381979D1 (de) | Verfahren zur photometrischen bestimmung biologischer agglutinaten. | |
| ATE81722T1 (de) | Verfahren zur bestimmung von mimotopen. | |
| AR230954A1 (es) | Un metodo mejorado de separacion y concentracion de la proteina de actividad pro-coagulante viii:c a partir de un complejo de factor viii que contiene viii:c y viii:rp y un inmunoabsorbente empleado | |
| ATA328286A (de) | Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa | |
| DE69022786D1 (de) | Verfahren zur Bestimmung der Konzentration von Glucose. | |
| DE3876273D1 (de) | Isoelektrisches fokussierverfahren sowie einrichtung zur durchfuehrung dieses verfahrens. | |
| FI895959A7 (fi) | Koostumus, diagnostinen käyttöpakkaus ja menetelmä vasta-aineiden nope aksi toteamiseksi | |
| DE3788762D1 (de) | Verfahren zur Bestimmung von physiologisch wirksamen Substanzen. | |
| DE3777417D1 (de) | Verfahren zur kryokonservierung von herzklappen. | |
| ATA426079A (de) | Verfahren zur quantitativen enzymatischen bestimmung von adp | |
| DE3863285D1 (de) | Verfahren und reagenz zur bestimmung von persaeuren. | |
| DE3689218D1 (de) | Verfahren zur differenzierten Bestimmung weisser Blutkörperchen. | |
| ATE10013T1 (de) | Verfahren und reagens zur bestimmung von glycerin. | |
| DK164973C (da) | Undersoegelsesmetode til bestemmelse af 1,25-dihydroxy vitamin d og saet til brug ved denne metode | |
| DE68906650D1 (de) | Verfahren zur zementierung von plattformbeinen. | |
| DE3583875D1 (de) | Verfahren zur herstellung von kugelfoermigen vollblut-erythrocyten und fixierung derselben. | |
| NO874453L (no) | Fremgangsmaate til bestemmelse av anti-hiv, middel dertil og dets anvendelse i fremgangsmaaten. | |
| DE3875825D1 (de) | Verfahren zur bestimmung der absorption von thyroxin. | |
| FI882265A7 (fi) | Menetelmä fruktosamiinin määrittämiseksi. | |
| FI895215A7 (fi) | Menetelmä antitrombiini III:n biologisen aktiivisuuden määrittämiseksi ja reagenssi sitä varten | |
| FI854627A7 (fi) | Menetelmä ja reagenssi plasmassa, seerumissa tai kokoveressä olevan vapaan tyroksiinin kvantitatiiviseksi määrittämiseksi. | |
| DE3585238D1 (de) | Verfahren zur bestimmung des reduzierten zustands von nicotinamid-adenin-dinukleotid. | |
| DE69026611D1 (de) | Verfahren zur Bestimmung von Fruktosaminen | |
| DE68914252D1 (de) | Verfahren zur Bestimmung eines Antigens. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |